Halozyme Therapeutics, Inc.

567 articles about Halozyme Therapeutics, Inc.

• Halozyme to Present at Upcoming Investor Conferences - November 27, 2023

  11/27/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences. 

• Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

  11/16/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received European Commission (EC) approval of VYVGART® SC (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE® for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

• Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

  11/6/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme's ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target.

• HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS

  11/6/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter ended September 30, 2023 and provided an update on its recent corporate activities and outlook.

• Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

  11/6/2023

  Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc.

• Halozyme To Report Third Quarter 2023 Financial and Operating Results

  10/30/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, November 6, 2023, following the close of trading.

• Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  10/19/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from the Phase 3 CheckMate-67T trial evaluating a subcutaneous (SC) formulation of Opdivo (nivolumab) with ENHANZE® in patients with advanced or metastatic clear cell renal cell carcinoma.

• Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference

  10/16/2023

  Halozyme Therapeutics, Inc. will present the positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds, at the 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference.

• Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

  10/16/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds.

• Halozyme to Present at Upcoming September 2023 Investor Conferences

  8/31/2023

  Halozyme Therapeutics, Inc. announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences.

• Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

  8/29/2023

  Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC, using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.

• Halozyme Reports Second Quarter 2023 Financial and Operating Results

  8/8/2023

  Halozyme Therapeutics, Inc. reported its financial and operating results for the second quarter ended June 30, 2023 and provided an update on its recent corporate activities and outlook.

• Halozyme To Report Second Quarter 2023 Financial and Operating Results

  7/25/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, following the close of trading.

• Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

  7/13/2023

  Halozyme Therapeutics, Inc. announced that Roche's Phase 3 OCARINA II trial evaluating OCREVUS® with ENHANZE® as a twice a year 10-minute subcutaneous injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis or primary progressive MS.

• Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

  6/20/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE® for subcutaneous (SC) use for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

• Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

  6/6/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 , at 8 a.m. PT / 11 a.m. ET .

• Halozyme Reports First Quarter 2023 Financial and Operating Results

  5/9/2023

  Halozyme Therapeutics, Inc. reported its financial and operating results for the first quarter ended March 31, 2023 and provided an update on its recent corporate activities and outlook.

• Halozyme to Present at Upcoming Investor Conferences

  5/3/2023

  Halozyme Therapeutics, Inc. today announced that Dr. Helen Torley , president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences.  

• Halozyme To Report First Quarter 2023 Financial and Operating Results

  4/25/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating results on Tuesday, May 9, 2023, following the close of trading.

• HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

  3/15/2023

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today provides an update on a decision by the Opposition Division of the European Patent Office ("EPO") regarding one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC.